Want to see REPL full AI Analyst Report?
REPL Stock Chart & Stats
$2.17
$0.17(1.56%)
At close: 4:00 PM EST
$2.17
$0.17(1.56%)
Day’s Range― - ―
52-Week Range$1.50 - $13.24
Previous CloseN/A
Volume95.41K
Average Volume (3M)5.34M
Market Cap
$933.47M
Enterprise Value$779.12M
Total Cash (Recent Filing)$268.89M
Total Debt (Recent Filing)$28.28M
Price to Earnings (P/E)―
Beta0.25
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.38
Shares Outstanding83,945,160
10 Day Avg. Volume3,354,563
30 Day Avg. Volume5,336,563
Financial Highlights & Ratios
PEG Ratio-0.22
Price to Book (P/B)4.27
Price to Sales (P/S)0.00
P/FCF Ratio-2.49
Enterprise Value/Market Cap0.83
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.48
Forecast
1Y Price Target
$9.60Price Target Upside342.40% Upside
Rating ConsensusHold
Number of Analyst Covering8
EPS Forecast (FY)-2.17
Revenue Forecast (FY)$22.17M
Bulls Say, Bears Say
Bulls Say
Regulatory ProgressAcceptance of the RP1 BLA as a complete, Class 1 resubmission with a set action date and advisory committee creates a defined regulatory timeline and formal review pathway. This materially reduces long-term binary uncertainty and, if favorable, would enable transition from clinical-stage to commercial-stage operations.
Durable Clinical Efficacy (RP1)Three-year overall survival and durable response data in anti‑PD‑1 failed melanoma signal a clinically meaningful benefit in an underserved population. Durable efficacy supports favorable benefit-risk, payer coverage prospects, and lasting differentiation versus alternatives if regulatory approval is achieved.
Modest Leverage / Financial FlexibilityRelatively low debt levels give the company more financial flexibility to manage development timelines, pursue partnerships, or absorb trial delays. This structural balance-sheet feature reduces near-term insolvency risk versus highly leveraged peers and supports strategic optionality while clinical programs progress.
Bears Say
No Commercial RevenueAbsence of product revenue means the firm lacks an internal cash-generating engine and remains fully dependent on external financing until commercialization. This structural profile lengthens time to self-sufficiency and increases execution risk if clinical or regulatory setbacks delay approval or launch.
High And Rising Cash BurnSustained, large negative operating cash flow rapidly depletes cash reserves and forces repeated capital raises. High burn constrains the ability to advance multiple programs simultaneously and elevates the likelihood of dilutive financings, making long-term program continuity dependent on successful funding or partnerships.
Eroding Equity Base / Financing RiskA materially shrunken equity base reduces the capital cushion against ongoing losses, raising the probability of dilutive share issuances or unfavorable financing terms. This structural weakening limits strategic flexibility, could impair investor confidence, and pressures management to prioritize near-term funding over broader R&D expansion.
Replimune Group News
REPL FAQ
What was Replimune Group’s price range in the past 12 months?
Replimune Group lowest stock price was $1.50 and its highest was $13.24 in the past 12 months.
What is Replimune Group’s market cap?
Replimune Group’s market cap is $933.47M.
When is Replimune Group’s upcoming earnings report date?
Replimune Group’s upcoming earnings report date is Aug 06, 2026 which is in 28 days.
How were Replimune Group’s earnings last quarter?
Replimune Group released its earnings results on Jun 29, 2026. The company reported -$0.76 earnings per share for the quarter, missing the consensus estimate of -$0.661 by -$0.099.
Is Replimune Group overvalued?
According to Wall Street analysts Replimune Group’s price is currently Undervalued.
Does Replimune Group pay dividends?
Replimune Group does not currently pay dividends.
What is Replimune Group’s EPS estimate?
Replimune Group’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Replimune Group have?
Replimune Group has 83,945,160 shares outstanding.
What happened to Replimune Group’s price movement after its last earnings report?
Replimune Group reported an EPS of -$0.76 in its last earnings report, missing expectations of -$0.661. Following the earnings report the stock price went down -3.697%.
Which hedge fund is a major shareholder of Replimune Group?
Currently, no hedge funds are holding shares in REPL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Replimune Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$9.60 (342.40% Upside)
$9.60 (342.40% Upside)
Blogger Sentiment
Bullish
REPL Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 132.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $474.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 2.5%
Last 30 Days ▲ 2.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
19.27%
12-Months-Change
Fundamentals
Return on Equity
-102.69%
Trailing 12-Months
Asset Growth
-39.71%
Trailing 12-Months
Company Description
Replimune Group
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
REPL Stock 12 Month Forecast
Average Price Target
$9.60
▲(342.40% Upside)
Technical Analysis
Anavex Life Sciences
―
Arcus Biosciences
―
Oric Pharmaceuticals
―
Nurix Therapeutics
―
Sana Biotechnology
―
Ownership Overview
3.49% Insiders
17.42% Mutual Funds
0.02% Other Institutional Investors
64.37% Public Companies and
Individual Investors